IXICO plc (GB:IXI) has released an update.
IXICO plc, a leader in medical imaging analytics, has announced a significant contract win with the Global Alzheimer’s Platform Foundation to support the Bio-Hermes 2 trial, aimed at advancing Alzheimer’s research. The contract, valued at over £1 million for a 48-month period, will not alter the company’s FY24 financial performance projections. IXICO will leverage its expertise in imaging and AI analysis to work with approximately 1,200 volunteers across different stages of Alzheimer’s, highlighting its commitment to addressing the unmet medical needs in Alzheimer’s therapies.
For further insights into GB:IXI stock, check out TipRanks’ Stock Analysis page.
